Expression of sex steroid receptors and aromatase in adipose tissue in different body regions in men with coronary artery disease with and without ischemic systolic heart failure

References

• Clark AL, Poole-Wilson PA, Coats AJ. Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol. 1996;28:1092–1102.
   PubMed Web of Science ®Google Scholar
• Coats AJS. Heart failure: what causes the symptoms of heart failure? Heart. 2001;86:574–578.
   PubMed Web of Science ®Google Scholar
• Coats AJ, Clark AL, Piepoli M, et al. Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J. 1994;72:S36–S39.
   PubMedGoogle Scholar
• Jankowska EA, Ponikowski P, Piepoli MF, et al. Autonomic imbalance and immune activation in chronic heart failure – pathophysiological links. Cardiovasc Res. 2006;70:434–445.
   PubMed Web of Science ®Google Scholar
• Almehmadi Y, Yassin DJ, Yassin AA. Erectile dysfunction is a prognostic indicator of comorbidities in men with late onset hypogonadism. Aging Male. 2015;18:186–194.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Morris PD, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96:1821–1825.
   PubMed Web of Science ®Google Scholar
• Kapoor D, Aldred H, Clark S, et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007;30:911–917.
   PubMed Web of Science ®Google Scholar
• Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8:272–283.
   PubMed Web of Science ®Google Scholar
• Ding EL, Song Y, Malik VS, et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295:1288–1299.
   PubMed Web of Science ®Google Scholar
• Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation. 2007;116:2694–2701.
   PubMed Web of Science ®Google Scholar
• Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93:68–75.
   PubMed Web of Science ®Google Scholar
• Ponikowska B, Jankowska EA, Maj J, et al. Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. Int J Cardiol. 2010;143:343–348.
   PubMed Web of Science ®Google Scholar
• Schipf S, Haring R, Friedrich N, et al. Low total testosterone is associated with increased risk of incident type 2 diabetes mellitus in men: results from the study of health in Pomerania (SHIP)). Aging Male. 2011;14:168–175.
   PubMed Web of Science ®Google Scholar
• Haidar A, Yassin A, Saad F, et al. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male. 2007;10:189–196.
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006;114:1829–1837.
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Rozentryt P, Ponikowska B, et al. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 2009;301:1892–1901.
   PubMed Web of Science ®Google Scholar
• Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med. 2005;2:536–543.
   PubMedGoogle Scholar
• Sacks HS, Fain JN. Human epicardial adipose tissue: a review. Am Heart J. 2007;153:907–917.
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666–3672.
   PubMed Web of Science ®Google Scholar
• Sodergard R, Backstrom T, Shanbhag V, et al. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982;16:801–810.
   PubMedGoogle Scholar
• Jankowska EA, Filippatos G, Ponikowska B, et al. Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J Card Fail. 2009;15:442–450.
   PubMed Web of Science ®Google Scholar
• Jankowska EA, Drohomirecka A, Ponikowska B, et al. Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure. Eur J Heart Fail. 2010;12:966–973.
   PubMed Web of Science ®Google Scholar
• Corona G, Forti G, Maggi M. Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male. 2008;11:193–199.
   PubMed Web of Science ®Google Scholar
• Rabijewski M, Papierska L, Piątkiewicz P. The prevalence of prediabetes in population of Polish men with late-onset hypogonadism. Aging Male. 2014;17:141–146.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Saad F, Haider A, et al. The role of the urologist in the prevention and early detection of cardiovascular disease. Arab J Urol. 2011;9:57–62.
   PubMedGoogle Scholar
• Chen RY, Wittert GA, Andrews GR. Relative androgen deficiency in relation to obesity and metabolic status in older men. Diabetes Obes Metab. 2006;8:429–435.
   PubMed Web of Science ®Google Scholar
• Saad F, Yassin A, Almehmadi Y, et al. Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus – a series of case reports. Aging Male. 2015;18:164–168.
   PubMed Web of Science ®Google Scholar
• Kapoor D, Malkin CJ, Channer KS, et al. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf). 2005;63:239–250.
   PubMed Web of Science ®Google Scholar
• Cohen P. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt – a major factor in the genesis of morbid obesity. Med Hypotheses. 1999;52:49–51.
   PubMed Web of Science ®Google Scholar
• Corona G, Mannucci E, Fisher AD, et al. Low levels of androgens in men with erectile dysfunction and obesity. J Sex Med. 2008;5:2454–2463.
   PubMed Web of Science ®Google Scholar
• Zumoff B, Strain GW, Miller LK, et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab. 1990;71:929–931.
   PubMed Web of Science ®Google Scholar
• Ho CH, Wu CC, Chen KC, et al. Erectile dysfunction, loss of libido and low sexual frequency increase the risk of cardiovascular disease in men with low testosterone. Aging Male. 2016;19:96–101.
   PubMed Web of Science ®Google Scholar
• Tamler R, Deveney T. Hypogonadism, erectile dysfunction, and type 2 diabetes mellitus: what the clinician needs to know. Postgrad Med. 2010;122:165–175.
   PubMed Web of Science ®Google Scholar
• Leoni LA, Fukushima AR, Rocha LY, et al. Physical activity on endothelial and erectile dysfunction: a literature review. Aging Male. 2014;17:125–130.
   PubMed Web of Science ®Google Scholar
• Salman M, Yassin DJ, Shoukfeh H, et al. Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy. Aging Male. 2017;20:45–48.
   PubMed Web of Science ®Google Scholar
• Yassin A, Almehmadi Y, Saad F, et al. The author's reply: changing testosterone had no direct effect on HbA1c or weight in diabetic men when TRT was interrupted and then resumed. Clin Endocrinol. 2016;85:500–501.
   PubMed Web of Science ®Google Scholar
• Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6:1–7.
   PubMedGoogle Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19:64–69.
   PubMed Web of Science ®Google Scholar
• Mårin P, Odén B, Björntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab. 1995;80:239–243.
   PubMed Web of Science ®Google Scholar
• Navarro G, Xu W, Jacobson DA, et al. Extranuclear actions of the androgen receptor enhance glucose-stimulated insulin secretion in the male. Cell Metab. 2016;23:837–851.
   PubMed Web of Science ®Google Scholar
• Dhindsa S, Ghanim H, Batra M, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Dia Care. 2016;39:82–91.
   PubMed Web of Science ®Google Scholar
• Yialamas MA, Dwyer AA, Hanley E, et al. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2007;92:4254–4259.
   PubMed Web of Science ®Google Scholar
• Jones TH. Cardiovascular risk during androgen deprivation therapy for prostate cancer. BMJ. 2011;342:d3105.
   PubMedGoogle Scholar
• Mazur A, Westerman R, Werdecker A, et al. Testosterone and type 2 diabetes in men. Aging Male. 2014;17:18–24.
   PubMed Web of Science ®Google Scholar
• Eri LM, Haug E, Tveter KJ. Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia. Scand J Clin Lab Invest. 1996;56:319–325.
   PubMed Web of Science ®Google Scholar
• Peters AA, Buchanan G, Ricciardelli C, et al. Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Cancer Res. 2009;69:6131–6140.
   PubMedGoogle Scholar
• Smith P, Rhodes NP, Ke1 Y, et al. Upregulation of estrogen and androgen receptors modulate expression of FGF-2 and FGF-7 in human, cultured, prostatic stromal cells exposed to high concentrations of estradiol. Prostate Cancer Prostatic Dis. 2002;5:105–110.
   PubMed Web of Science ®Google Scholar